Literature DB >> 15265266

Relevance of functional neuroimaging in the progression of mild cognitive impairment.

José A Cabranes1, Ramón De Juan, Marta Encinas, Alberto Marcos, Pedro Gil, Cristina Fernández, Carmen De Ugarte, Ana Barabash.   

Abstract

AIM: To assess whether combining neuropsychological tests and cerebral blood flow markers improves progression accuracy from mild cognitive impairment (MCI) to Alzheimer's disease (AD) than each of them on its own.
METHODS: Forty-two patients were investigated prospectively, undergoing baseline and 3-year follow-up neuropsychological tests and neuroimaging with Tc-ECD-SPECT. Twenty-one patients had developed AD while 21 retained their initial diagnosis. The relative blood flow and cognitive differences were studied. Validity parameters, multivariant analysis and logistic regression model were calculated.
RESULTS: Patients who deteriorated showed lower scoring than stable subjects in some neuropsychological tests (p = 0.03-0.001) and in relative blood flow in selected regions (8-10%). Low cognitive test scoring and low relative blood flow in some regions showed sensibilities and specificities from 70% to 86% for the diagnosis of early Alzheimer's disease. The relative risk of progression to AD was up to 4.7 times higher for these patients (p = 0.0001). The left frontal relative blood flow, the CAMCOG and orientation scoring were the best data to predict the risk of progression to AD.
CONCLUSIONS: The combination of functional imaging and neuropsychological tests can diagnose with high sensitivity and specificity if a patient is suffering cognitive impairment in its early stages, and may aid in predicting the risk of developing dementia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265266     DOI: 10.1179/016164104225016155

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  4 in total

1.  Volume cerebral blood flow reduction in pre-clinical stage of Alzheimer disease: evidence from an ultrasonographic study.

Authors:  Nabil Maalikjy Akkawi; B Borroni; C Agosti; M Magoni; M Broli; A Pezzini; A Padovani
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

2.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

3.  Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment.

Authors:  A Caroli; C Testa; C Geroldi; F Nobili; L R Barnden; U P Guerra; M Bonetti; G B Frisoni
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

4.  The correlation of neuropsychological evaluation with 11C-PiB and 18F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease.

Authors:  Su Yeon Park; Byung Hyun Byun; Byung Il Kim; Sang Moo Lim; In Ok Ko; Kyo Chul Lee; Kyeong Min Kim; Yu Kyeong Kim; Jun-Young Lee; Seon Hee Bu; Jung Hwa Kim; Dae Yoon Chi; Jeong Ho Ha
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.